Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor α gene expression

Cancer Research

Volumn 57, Issue 16, 1997, Pages 3339-3343

  Hu, Shi Xue ^a   Ji, Wan ^a   Zhou, Yunli ^a   Logothetis, Christopher ^b   Xu, Hong Ji ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PRIORITY JOURNAL; REPRESSOR GENE; T LYMPHOCYTE; TUMOR CELL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CELL LINE; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; PROTEIN SYNTHESIS INHIBITORS; RECOMBINANT PROTEINS; TETRACYCLINE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030761734     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fiers, W. Tumor necrosis factor: characterization at the molecular, cellular, and in vivo level. FEBS Lett., 285: 199-212, 1991.
2. Asher, A., Mule, J. J., Reichen, C. M., Shiloni, E., and Rosenberg, S. A. Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J. Immunol., 138: 963-974, 1987.
3. Sidhu, R. S., and Bollon, A. P. Tumor necrosis factor activities and cancer therapy: a perspective. Pharmacol. & Ther., 57: 79-128, 1993.
4. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., and Lejeune, F. J. High-dose recombinant tumor necrosis factor α in combination with Interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
5. Pass, H. I., Mew, D. J., Kranda, K. C., Temeck, B. K., Donington, J. S., and Rosenberg, S. A. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann. Thorac. Surg., 61: 1609-1617, 1996.
6. Marincola, F. M., Ettinghausen, S., Cohen, P. A., Cheshire, L. B,. Restifo, N. P., Mule, J. J., and Rosenberg, S. A. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. J. Immunol., 152: 3500-3513, 1994.
7. Treisman, J., Hwu, P., Yannelli, J. R., Shafer, G. E., Cowherd, R., Samid, D., and Rosenberg, S. A. Up-regulation of tumor necrosis factor α production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell. Immunol., 156: 448-457, 1994.
8. Hwu, P., Yannelli, J., Kriegler, M., Anderson, W. F., Perez, C., Chiang, Y., Schwarz, S., Cowherd, R., Delgado, C., Mule, J., and Rosenberg, S. A. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor α cDNA for the gene therapy of cancer in humans. J. Immunol., 150: 4104-4115, 1993.
9. Muro-Cacho, C. A., Samulski, R. J., and Kaplan, D. Gene transfer in human lymphocytes using a vector based on adeno-associated virus. J. Immunother., 11: 231-237, 1992.
10. Abe, J., Wakimoto, H., Tsunoda, R., Okabe, S., Yoshida, Y., Aoyagi, M., Hirakawa, K, and Hamada, H. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon γ by adenovirus-mediated genetic transduction. Bioehem. Biophys. Res. Commun. 218: 164-170, 1996.
11. Gossen, M., and Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89: 5547-5551, 1992.
12. Aggarwal, B. B., and Kohr, W. J. Human tumor necrosis factor. Methods Enzymol., 116: 448-456, 1985.
13. Muench, M. O., Roncarolo, M. G., Namikawa, R., Barcena, A., and Moore, M. A. Progress in the ex vivo expansion of hematopoietic progenitors. Leuk. Lymphoma, 16: 1-11, 1994.
14. Gill, G., and Ptashne, M. Negative effect of the transcriptional activator GAL4. Nature (Lond.), 334: 721-724, 1988.
15. Graham, F. L., and Prevec, L. Manipulation of adenovirus vectors. In: E. J. Murray (ed.), Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols, pp. 109-128. Clifton, NJ: Humana Press, Inc., 1991.
16. Xu, H. J., Zhou, Y., Seigne, J., Perng, G. S., Mixon, M., Zhang, C., Li, J., Benedict, W. F., and Hu, S. X. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res., 56: 2245-2249, 1996.
17. Shisler, J., Duerksen-Hughes, P., Hermiston, T. M., Wold, W. S., and Gooding, L. R. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. J. Virol., 70: 68-77, 1996.
18. Sensibar, J. A., Sutkowski, D. M., Raffo, A., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res., 55: 2431-2437, 1995.
19. Peters, W. P., Rosner, G., Ross, M., Vredenburgh, J., Meisenberg, B., Gilbert, C., and Kurtzberg, J. Comparative effects of granulocyte macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood, 81: 1709-1719, 1993.
20. Wickham, T. J., Roelvink, P. W., Brough, D. E., and Kovesdi, I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 14: 1570-1573, 1996.
21. Hersh, E. M., Metch, B. S., Muggia, F. M., Brown, T. D., Whitehead, R. P., Budd, G. T., Rinehart, J. J., Crawford, E. D., Bonnet, J. D., and Behrens, B. C. Phase II studies of recombinant human tumor necrosis factor α in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother., 10: 426-431, 1991.
22. Van Ostade, X., Vandenabeele, P., Everaerdt, B., Loetscher, H., Gentz, R., Brockhaus, M., Lesslauer, W., Tavernier, J., Brouckaert, P., and Fiers, W. Human TNF mutants with selective activity on the p55 receptor. Nature (Lond.), 361: 266-269, 1993.
23. Rathjen, D. A., Furphy, L. J., and Aston, R. Selective enhancement of the tumour necrotic activity of TNF-α with monoclonal antibody. Br. J. Cancer, 65: 852-856, 1992.
24. Metcalf, J. P., Monick, M. M., Stinski, M. F., and Hunninghake, G. W. Adenovirus E1A 13S gene product up-regulates the cytomegalovirus major immediate early promoter. Am. J. Respir. Cell Mol. Biol., 10: 448-452, 1994.